U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H22N2O2
Molecular Weight 250.3372
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIVASTIGMINE

SMILES

CCN(C)C(=O)Oc1cccc(c1)[C@]([H])(C)N(C)C

InChI

InChIKey=XSVMFMHYUFZWBK-NSHDSACASA-N
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1

HIDE SMILES / InChI
Rivastigmine (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. Rivastigmine, an acetylcholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase (unlike donepezil, which selectively inhibits acetylcholinesterase). It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain neurotransmitter acetylcholine. Rivastigmine capsules, liquid solution, and patches are used for the treatment of mild to moderate dementia of the Alzheimer's type and for mild to moderate dementia related to Parkinson's disease. Rivastigmine has demonstrated treatment effects on the cognitive (thinking and memory), functional (activities of daily living) and behavioral problems commonly associated with Alzheimer's and Parkinson's disease dementia. In people with either type of dementia, rivastigmine has been shown to provide meaningful symptomatic effects that may allow patients to remain independent and ‘be themselves’ for longer. In particular, it appears to show marked treatment effects in patients showing a more aggressive course of the disease, such as those with younger-onset ages, poor nutritional status, or those experiencing symptoms such as delusions or hallucinations. Side effects may include nausea and vomiting, decreased appetite and weight loss.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
54.0 nM [IC50]
30.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
EXELON

Approved Use

EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: Mild, moderate, and severe dementia of the Alzheimer’s type (1.1) Mild to moderate dementia associated with Parkinson’s disease (1.2) 1.1 Alzheimer’s Disease EXELON PATCH is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. 1.2 Parkinson’s Disease Dementia EXELON PATCH is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease (PDD).

Launch Date

1.18368004E12
Primary
EXELON

Approved Use

EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: Mild, moderate, and severe dementia of the Alzheimer’s type (1.1) Mild to moderate dementia associated with Parkinson’s disease (1.2) 1.1 Alzheimer’s Disease EXELON PATCH is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. 1.2 Parkinson’s Disease Dementia EXELON PATCH is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease (PDD).

Launch Date

1.18368004E12
Primary
EXELON

Approved Use

EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: Mild, moderate, and severe dementia of the Alzheimer’s type (1.1) Mild to moderate dementia associated with Parkinson’s disease (1.2) 1.1 Alzheimer’s Disease EXELON PATCH is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. 1.2 Parkinson’s Disease Dementia EXELON PATCH is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease (PDD).

Launch Date

1.18368004E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
37.23 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVASTIGMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
129.46 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVASTIGMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.76 h
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVASTIGMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
RIVASTIGMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12 mg single, oral
Overdose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
healthy, 3 years
n = 1
Health Status: healthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Other AEs: Cholinergic syndrome...
Other AEs:
Cholinergic syndrome (1 patient)
Sources:
90 mg single, oral
Overdose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
unknown, 38 years
n = 1
Health Status: unknown
Age Group: 38 years
Sex: M
Population Size: 1
Sources:
Other AEs: Respiratory depression, Dizziness...
Other AEs:
Respiratory depression (1 patient)
Dizziness (1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Sweating (1 patient)
Sources:
288 mg single, oral
Overdose
Dose: 288 mg
Route: oral
Route: single
Dose: 288 mg
Co-administed with::
citalopram(280 mg, single)
Sources:
unknown, 59 years
n = 1
Health Status: unknown
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Other AEs: Cholinergic syndrome...
Other AEs:
Cholinergic syndrome (1 patient)
Sources:
9.5 mg 6 times / day multiple, transdermal
Overdose
Dose: 9.5 mg, 6 times / day
Route: transdermal
Route: multiple
Dose: 9.5 mg, 6 times / day
Sources:
unhealthy, 87 years
n = 1
Health Status: unhealthy
Condition: dementia
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (grade 5)
Vomiting (grade 5)
Renal failure (grade 5)
Sources:
17.4 mg 1 times / day multiple, transdermal
Highest studied dose
Dose: 17.4 mg, 1 times / day
Route: transdermal
Route: multiple
Dose: 17.4 mg, 1 times / day
Sources:
unhealthy
n = 303
Health Status: unhealthy
Population Size: 303
Sources:
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (1.7%)
Nausea (1.7%)
Sources:
10 mg 1 times / day multiple, oral (mean)
MTD
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Population Size: 45
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (58%)
Vomiting (38%)
Dizziness (27%)
Anorexia (18%)
Headache (16%)
Sources:
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy
n = 1189
Health Status: unhealthy
Population Size: 1189
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (8%)
Vomiting (4%)
Anorexia (2%)
Dizziness (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cholinergic syndrome 1 patient
12 mg single, oral
Overdose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
healthy, 3 years
n = 1
Health Status: healthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Dizziness 1 patient
90 mg single, oral
Overdose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
unknown, 38 years
n = 1
Health Status: unknown
Age Group: 38 years
Sex: M
Population Size: 1
Sources:
Nausea 1 patient
90 mg single, oral
Overdose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
unknown, 38 years
n = 1
Health Status: unknown
Age Group: 38 years
Sex: M
Population Size: 1
Sources:
Respiratory depression 1 patient
90 mg single, oral
Overdose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
unknown, 38 years
n = 1
Health Status: unknown
Age Group: 38 years
Sex: M
Population Size: 1
Sources:
Sweating 1 patient
90 mg single, oral
Overdose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
unknown, 38 years
n = 1
Health Status: unknown
Age Group: 38 years
Sex: M
Population Size: 1
Sources:
Vomiting 1 patient
90 mg single, oral
Overdose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
unknown, 38 years
n = 1
Health Status: unknown
Age Group: 38 years
Sex: M
Population Size: 1
Sources:
Cholinergic syndrome 1 patient
288 mg single, oral
Overdose
Dose: 288 mg
Route: oral
Route: single
Dose: 288 mg
Co-administed with::
citalopram(280 mg, single)
Sources:
unknown, 59 years
n = 1
Health Status: unknown
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Nausea grade 5
9.5 mg 6 times / day multiple, transdermal
Overdose
Dose: 9.5 mg, 6 times / day
Route: transdermal
Route: multiple
Dose: 9.5 mg, 6 times / day
Sources:
unhealthy, 87 years
n = 1
Health Status: unhealthy
Condition: dementia
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
Renal failure grade 5
9.5 mg 6 times / day multiple, transdermal
Overdose
Dose: 9.5 mg, 6 times / day
Route: transdermal
Route: multiple
Dose: 9.5 mg, 6 times / day
Sources:
unhealthy, 87 years
n = 1
Health Status: unhealthy
Condition: dementia
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
Vomiting grade 5
9.5 mg 6 times / day multiple, transdermal
Overdose
Dose: 9.5 mg, 6 times / day
Route: transdermal
Route: multiple
Dose: 9.5 mg, 6 times / day
Sources:
unhealthy, 87 years
n = 1
Health Status: unhealthy
Condition: dementia
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
Nausea 1.7%
Disc. AE
17.4 mg 1 times / day multiple, transdermal
Highest studied dose
Dose: 17.4 mg, 1 times / day
Route: transdermal
Route: multiple
Dose: 17.4 mg, 1 times / day
Sources:
unhealthy
n = 303
Health Status: unhealthy
Population Size: 303
Sources:
Vomiting 1.7%
Disc. AE
17.4 mg 1 times / day multiple, transdermal
Highest studied dose
Dose: 17.4 mg, 1 times / day
Route: transdermal
Route: multiple
Dose: 17.4 mg, 1 times / day
Sources:
unhealthy
n = 303
Health Status: unhealthy
Population Size: 303
Sources:
Headache 16%
10 mg 1 times / day multiple, oral (mean)
MTD
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Population Size: 45
Sources:
Anorexia 18%
10 mg 1 times / day multiple, oral (mean)
MTD
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Population Size: 45
Sources:
Dizziness 27%
10 mg 1 times / day multiple, oral (mean)
MTD
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Population Size: 45
Sources:
Vomiting 38%
10 mg 1 times / day multiple, oral (mean)
MTD
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Population Size: 45
Sources:
Nausea 58%
10 mg 1 times / day multiple, oral (mean)
MTD
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Population Size: 45
Sources:
Anorexia 2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy
n = 1189
Health Status: unhealthy
Population Size: 1189
Sources:
Dizziness 2%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy
n = 1189
Health Status: unhealthy
Population Size: 1189
Sources:
Vomiting 4%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy
n = 1189
Health Status: unhealthy
Population Size: 1189
Sources:
Nausea 8%
Disc. AE
6 mg 1 times / day multiple, oral
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy
n = 1189
Health Status: unhealthy
Population Size: 1189
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
2001
A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
2001
[Perspectives for drug treatment in Alzheimer's disease].
2001 Dec
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
2002
Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis.
2002
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
2002
Galantamine for Alzheimer's disease.
2002
Cholinergic medication for neuroleptic-induced tardive dyskinesia.
2002
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
2002
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
2002
Cutaneous drug reaction case reports: from the world literature.
2002
Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.
2002
Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system.
2002
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
2002 Apr
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
2002 Apr
Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
2002 Aug
SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
2002 Aug
Clinical use of cholinomimetic agents: a review.
2002 Aug
Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation.
2002 Aug 13
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
2002 Aug 27
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
2002 Aug-Oct
Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease.
2002 Jan 21
Medical treatment of Alzheimer's disease: past, present, and future.
2002 Jul
Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.
2002 Jul
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
2002 Jul
Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
2002 Jul-Aug
Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease.
2002 Jun
Switching cholinesterase inhibitors in patients with Alzheimer's disease.
2002 Jun
Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
2002 Jun
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
2002 Jun
Do cholinesterase inhibitors slow progression of Alzheimer's disease?
2002 Jun
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
2002 Jun
Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
2002 Jun
[Nicotinic Receptor, galantamine and Alzheimer disease].
2002 Jun 1-15
Guidelines for managing Alzheimer's disease: Part II. Treatment.
2002 Jun 15
[Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report].
2002 Mar
Rivastigmin and impaired motor function.
2002 Mar
Understanding changes in cholinergic function: implications for treating dementia.
2002 Mar
Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
2002 Mar
Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.
2002 Mar 19
[Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
2002 Mar 9
Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine.
2002 Mar-Apr
In vitro toxicity of rivastigmine and donepezil in cells of epithelial origin.
2002 Mar-Apr
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
2002 May
Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
2002 May
Pharmacologic treatments of dementia.
2002 May
Electrocardiographic effects of rivastigmine.
2002 May
Prolonged QT interval with rivastigmine.
2002 May
The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.
2002 May
[Dementing disorders. What benefits do the new anti-dementia drugs have?].
2002 May 6
Patents

Sample Use Guides

Oral (Indicated for mild-to-moderate dementia of the Alzheimer's type): Initial: 1.5 mg PO q12hr; Increase by 1.5 mg/dose q2Weeks; not to exceed 6 mg PO q12hr; Maintenance: 3-6 mg PO q12hr (higher end may be more beneficial); Transdermal (Indicated for mild, moderate, and severe dementia of the Alzheimer's type): Initial: Apply 4.6 mg q24hr; Dose titration: May increase dose to 9.5 mg q24hr after a minimum 4 weeks if well tolerated; after an additional 4 weeks, may further increase to 13.3 mg patch if needed; Mild-to-moderate Alzheimer disease: Effective dosage range is 9.5-13.3 mg/24 hr; Moderate-to-severe Alzheimer disease: Effective dose is 13.3 mg/24 hr; Replace with new patch q24hr
Route of Administration: Other
The cytotoxicity of empty and Rivastigmine-loaded PHEA-EDASq17-PS80 micelles was evaluated on mouse neuroblastoma (Neuro2a) cell lines. cCells were seeded in 96 well plate at a density of 5×104 cells/well and grown in Minimum Essential Medium (MEM) with 10% FBS (fetal bovine serum) and 1% of penicillin/streptomycin (10,000U mL−1 penicillin and 10mg mL−1 streptomycin) at 37°C in 5% CO2 humidified atmosphere. After 72h of incubation, cells were treated with Riv-loaded micelles solutions in bidistilled water, having micelle concentrations of 1, 0.5 and 0.25mg/mL. Aliquots of micelle solutions (10 µL) were added to the cells in 100 µL fresh medium and incubated for 6, 24 and 48h. After incubation, 20 µL of MTT reagent solution [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide, Sigma; 0.5mg mL−1)] were added to each well and plates were incubated at 37°C for 2h; the absorbance was then measured by a multiwell plate reader (Multiskan Ex, Thermo absystems, Finland), at 490nm after background correction. Cells treated with Riv (Rivastigmine) solutions in DMSO, with drug concentration of 0.1, 0.2 and 0.05mg/mL, were used as positive control
Name Type Language
RIVASTIGMINE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
RIVASTIGMINE [EP MONOGRAPH]
Common Name English
ENA-713D
Code English
RIVASTIGMINE [MART.]
Common Name English
RIVASTIGMINE 1 A PHARMA
Brand Name English
RIVASTIGMINE 3M HEALTH CARE LTD
Brand Name English
NIMVASTID
Brand Name English
SDZ-212-713
Code English
SDZ-212713
Code English
RIVASTIGMINE [ORANGE BOOK]
Common Name English
RIVASTIGMINE [WHO-DD]
Common Name English
RIVASTIGMINE TEVA
Brand Name English
PROMETAX
Brand Name English
ONO-2540
Code English
RIVASTIGMINE [EMA EPAR]
Common Name English
RIVASTIGMINE [JAN]
Common Name English
(S)-3-(1-(DIMETHYLAMINO)ETHYL)PHENYL ETHYLMETHYLCARBAMATE
Systematic Name English
RIVASTIGMINE [MI]
Common Name English
RIVASTIGMINE SANDOZ
Brand Name English
M-((S)-1-(DIMETHYLAMINO)ETHYL)PHENYL ETHYLMETHYLCARBAMATE
Systematic Name English
RIVASTIGMINE HEXAL
Brand Name English
RIVASTIGMINE [USAN]
Common Name English
RIVASTIGMINE [VANDF]
Common Name English
RIVASTIGMINE [INN]
Common Name English
EXELON
Brand Name English
RIVASTIGMINE [USP-RS]
Common Name English
RIVASTIGMINE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS RIVASTIGMINE SANDOZ
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS EXELON (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
WHO-VATC QN06DA03
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE TEVA (WITHDRAWN: ALZHEIMER DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE SANDOZ (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE HEXAL (AUTHORIZED: DEMENTIA)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS NIMVASTID (AUTHORIZED: ALZHEIMER DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS PROMETAX (AUTHORIZED: DEMENTIA)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS NIMVASTID (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
LIVERTOX 856
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS EXELON (AUTHORIZED: DEMENTIA)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE HEXAL (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
NDF-RT N0000000177
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
WHO-ATC N06DA03
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS PROMETAX (AUTHORIZED: ALZHEIMER DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
NDF-RT N0000175723
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
NCI_THESAURUS C47792
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS EXELON (AUTHORIZED: ALZHEIMER DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE 3M HEALTH CARE LTD (WITHDRAWN: ALZHEIMER DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS NIMVASTID (AUTHORIZED: DEMENTIA)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS PROMETAX (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE 1A PHARMA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE 1 A PHARMA (AUTHORIZED: ALZHEIMER DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE 1 A PHARMA (AUTHORIZED: DEMENTIA)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE SANDOZ (AUTHORIZED: DEMENTIA)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE TEVA (WITHDRAWN: PARKINSON DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE TEVA (WITHDRAWN: DEMENTIA)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
EMA ASSESSMENT REPORTS RIVASTIGMINE HEXAL (AUTHORIZED: ALZHEIMER DISEASE)
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
Code System Code Type Description
WIKIPEDIA
RIVASTIGMINE
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
INN
7562
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
PUBCHEM
77991
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
ChEMBL
CHEMBL636
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
USP_CATALOG
1604836
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY USP-RS
CAS
123441-03-2
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
IUPHAR
6602
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
MERCK INDEX
M9639
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY Merck Index
FDA UNII
PKI06M3IW0
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
DRUG CENTRAL
2392
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
RXCUI
183379
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY RxNorm
EVMPD
SUB10345MIG
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
EPA CompTox
123441-03-2
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
DRUG BANK
DB00989
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
MESH
C072506
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY
NCI_THESAURUS
C66519
Created by admin on Fri Jun 25 21:06:47 UTC 2021 , Edited by admin on Fri Jun 25 21:06:47 UTC 2021
PRIMARY